Correction to: Breast Cancer Research and Treatment (2020) 184:559–565 10.1007/s10549-020-05867-0
In the original publication, two values provided for landmark survival for patients treated with gemcitabine were incorrectly listed in the text. On page 562, paragraph 3, the text listed that “for TNBC: 50%, 31%, 20%, and 3%, respectively, for HR+/HER2−: 51%, 27%, 10%, and 3%, respectively”. The correct values should be “for TNBC: 50%, 31%, 11%, and 3%, respectively, for HR+/HER2−: 51%, 27%, 10%, and 7%, respectively”. The correct values are consistent with those listed in Table 2.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Contributor Information
Shayma Kazmi, Email: shayma.kazmi@ctca-hope.com, https://www.cancercenter.com.
Peter A. Kaufman, Email: peter.kaufman@uvmhealth.org